1. For the 4 months from September to December 2022, how many patients received the following anti-VEGF treatments for any eye condition:
Aflibercept
Bevacizumab
Brolucizumab
Dexamethasone
Faricimab
Ranibizumab – Lucentis
Ranibizumab – Ongavia
2. For the patients above, how many were new to anti-VEGF therapy? Please provide the patient numbers by the treatments listed below, excluding patients who previously had any anti-VEGF therapy.
Aflibercept
Bevacizumab
Brolucizumab
Dexamethasone
Faricimab
Ranibizumab – Lucentis
Ranibizumab – Ongavia